541FDA8B-9FAE-4346-A6FD-C56735C87920
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 12.483574244415243
- age_years
- 75
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.637
- MYC_TARGETS_V1+0.609
- G2M_CHECKPOINT+0.544
- MYC_TARGETS_V2+0.511
- MTORC1_SIGNALING+0.492
- DNA_REPAIR+0.491
- ANGIOGENESIS+0.478
- OXIDATIVE_PHOSPHORYLATION+0.460
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.387
- UNFOLDED_PROTEIN_RESPONSE+0.387
Top 10 suppressed
- KRAS_SIGNALING_DN-0.419
- MYOGENESIS-0.228
- ESTROGEN_RESPONSE_EARLY-0.170
- HEDGEHOG_SIGNALING-0.154
- BILE_ACID_METABOLISM-0.138
- SPERMATOGENESIS-0.086
- APICAL_SURFACE-0.081
- UV_RESPONSE_DN+0.021
- PANCREAS_BETA_CELLS+0.031
- ESTROGEN_RESPONSE_LATE+0.037
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | E24D233D-71BD-4EC2-A671-375917F24E5C | — | — | 0.959 |
| 2 | BB96C5BA-CA50-40B4-B22A-3FCFE46AB11C | — | — | 0.958 |
| 3 | 40CDF034-0EBC-42A1-BBD8-492C1494086E | — | — | 0.957 |
| 4 | EC1C727A-1F71-4C09-B867-7F163424D463 | — | — | 0.956 |
| 5 | AF548E30-7121-4F9F-A2CD-F1A540E9C4EE | — | — | 0.955 |
| 6 | 2E401C42-010F-4AFC-A362-B69426418626 | — | — | 0.950 |
| 7 | 4A54E284-9902-4E4C-A5BC-1BF144106EA3 | — | — | 0.950 |
| 8 | 94640BD8-E1D9-482D-A597-4790F6EEA6B7 | — | — | 0.950 |
| 9 | 1B326CC6-3916-4D1D-A238-7B3C42F3E6C6 | — | — | 0.950 |
| 10 | AFE5BFD1-AA9F-470A-A44F-341126F8057D | — | — | 0.949 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 43 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.637 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.609 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.544 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.511 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.492 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.491 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.478 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.460 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.387 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.387 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.380 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.376 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.357 | Inavolisib | — uncovered |
| COMPLEMENT | 0.347 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.344 | Inavolisib | — uncovered |
| APOPTOSIS | 0.323 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.308 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.302 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.297 | Idelalisib | — uncovered |
| HYPOXIA | 0.294 | Idelalisib | — uncovered |